Been digging into Berkshire Hathaway's recent moves and there's some interesting patterns emerging in the portfolio. Warren Buffett may have stepped back from the CEO chair, but his influence is still stamped all over where this company is putting its money.

So here's the thing - American Express just became Berkshire's second-largest holding at over $47 billion. Most people are freaking out because the stock pulled back nearly 20% from its December peak. The narrative is all about consumer spending collapsing and loan defaults rising. U.S. household debt hit a record $18.8 trillion with delinquencies at near-decade highs around 4.8%. Sounds brutal for a lender, right?

But here's what's getting overlooked. Amex isn't your typical credit card company. Their customer base skews wealthy, and that matters more than people think. During Q4, luxury spending on Amex cards actually jumped 15% year-over-year. That's nearly double the 8% growth in total billed business. When you're serving affluent borrowers, economic headwinds hit differently. This 20% pullback could be the discount opportunity you've been waiting for.

Then there's Constellation Brands, the Corona and Modelo play. Warren Buffett loaded up on this late last year and it's been underwater since. Alcohol consumption in the U.S. hit a multidecade low at 54% according to Gallup. On the surface, this looks like a bad bet. But the beverage business is cyclical. People cut back during tough times, then spending rebounds when confidence returns. Meanwhile, management's been cleaning house - divesting lower-margin wine brands that were just cluttering the portfolio. New CEO Nicholas Fink coming in should bring some fresh energy too.

Now, not every Buffett holding is worth copying. DaVita, the dialysis operator, is a cautionary tale. When Berkshire first bought in back in 2011, the healthcare reimbursement environment was reasonable. That's completely flipped. Revenue is up just 5% year-over-year but net income dropped 17%. It's a perfect example of how brutal the healthcare industry has become. Interestingly, Berkshire itself started quietly exiting this position last year. Even Warren Buffett's successor Greg Abel seems to agree it's not worth fighting this headwind.

The broader point? Warren Buffett's fingerprints are still all over this portfolio, and there's real wisdom in studying which positions he's holding and which ones he's abandoning. Sometimes what matters most isn't what the Oracle is buying - it's what he's selling.